Product Description
Piperacillin and tazobactam combination injection is used to treat bacterial infections in many different parts of the body (eg, stomach or bowel, lungs, skin, female reproductive organs). (Sourced from: https://www.mayoclinic.org/drugs-supplements/piperacillin-and-tazobactam-intravenous-route/description/drg-20072716)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Pneumonia, Bacterial | Pelvic Infection | Pneumonia | Urinary Tract Infections | Nephritis | Pyelonephritis
Known Adverse Events: Headache | Insomnia | Constipation | Diarrhea
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Chile, China, Colombia, Croatia, Estonia, Germany, Greece, Hungary, India, Ireland, Japan, Mexico, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Russia, Saudi Arabia, Spain, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: COVID-19|Enterobacteriaceae Infections|Influenza, Human|Pneumonia|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated
Phase 2: Bacteremia|Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Coinfection|Community-Acquired Infections|Pseudomonas Infections|Pyelonephritis|Respiratory Tract Infections|Urinary Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REMAP-CAP | P3 |
Recruiting |
Influenza, Human|Pneumonia|COVID-19 |
2026-02-01 |
|
| NCT04673175 | P2 |
Recruiting |
Pneumonia|Pseudomonas Infections|Bacteremia |
2025-12-31 |
|
| 2022-002636-31 | P3 |
Active, not recruiting |
Enterobacteriaceae Infections |
2025-12-09 |
|
| FRENCH24 ANIS | P3 |
Active, not recruiting |
Unknown |
2025-04-03 |